

## CLAIMS

We claim:

- 5 ~~1. A method for treating TNF-mediated inflammatory diseases which comprises administering to a mammal in need thereof a therapeutically effective amount of a TNF antagonist.~~
- 10 ~~2. A method according to claim 1, wherein the TNF-mediated inflammatory disease is arthritis.~~
- ~~3. A method according to claim 2, wherein the mammal is a human.~~
- 15 ~~4. A method according to claim 3, wherein the TNF antagonist is soluble human TNFR.~~
- ~~5. A method according to claim 4, wherein the soluble human TNFR is selected from the group consisting of soluble human Type I TNFR and soluble human Type II TNFR.~~
- 20 ~~6. A method according to claim 4, wherein the soluble human TNFR is fused to the Fc region of a human immunoglobulin molecule.~~
- ~~7. A method according to claim 2, wherein TNFR is administered in combination with~~
- 25 ~~IL-1R.~~
- ~~8. A method for treating arthritis in a mammal, comprising the step of administering to a mammal having arthritis an amount of soluble human TNFR ranging from about 0.1 mg/kg/week to about 100 mg/kg/week.~~
- 30 ~~9. A method according to claim 8, wherein the amount of soluble human TNFR ranges from about 0.5 mg/kg/week to about 50 mg/kg/week.~~

add  
DI

add  
EI